MedTrace Logo

Targin® for Chronic Pain Management in Patients With Spinal Cord Injury

NCT03179475 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 1

Last updated 2021-12-10

No results posted yet for this study

Summary

The study will be investigating the effectiveness of oxycodone-naloxone (brand name Targin®) at treating chronic pain in individuals with spinal cord injury. The goal of the study is to compare the effectiveness of Targin® at treating chronic pain in individuals with sub-acute and chronic spinal cord injury compared to opioid medication that is not compounded with naloxone.

Conditions

Interventions

DRUG

Oxycodone Naloxone Combination

A flexible dosing schedule will be used in this study. The dose and schedule will be based on the minimal amount of medication required to manage pain related to spinal cord injury. The dose and/or frequency will be titrated to the individual's pain level at the discretion of their regular attending physician and/or investigator. Oxycodone-Naloxone is available in the following oral dosages: 1. 5 mg oxycodone hydrocholoride / 2.5 mg naloxone hydrochloride 2. 10 mg oxycodone hydrocholoride / 5 mg naloxone hydrochloride 3. 20 mg oxycodone hydrocholoride / 10 mg naloxone hydrochloride 4. 40 mg oxycodone hydrocholoride / 20 mg naloxone hydrochloride

Sponsors & Collaborators

  • Purdue Pharma, Canada

    collaborator INDUSTRY

  • International Collaboration on Repair Discoveries

    collaborator OTHER

  • Vancouver Coastal Health

    collaborator OTHER_GOV

  • University of British Columbia

    lead OTHER

Principal Investigators

  • Andrei Krassioukov, MD,PhD,FRCPC · University of British Columbia

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-09-05
Primary Completion
2021-11-29
Completion
2021-11-29

Countries

  • Canada

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03179475 on ClinicalTrials.gov